-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Childhood low-grade gliomas (pLGGs) are the most common brain tumors in children .
Children's low-grade gliomas (pLGGs) are the most common brain tumors in children Children's low-grade gliomas (pLGGs) are the most common brain tumors inchildren
Recently, researchers have prioritized the functional prognosis of children with low-grade glioma.
This article reports the results of a PBTC Phase 2 trial in children with relapsed/progressive OPHGs, which evaluated the efficacy of the MEK-1/2 inhibitor selumetinib (selumetinib, AZD6244, ARRY-142886) in such patients.
A total of 25 evaluable patients with multiple conditions were included in the analysis, and the median number of previous treatment courses was 4 (1-11).
6 patients (24%) achieved partial remission, 14 (56%) had stable disease, 6 (24%) had partial remission, and 14 (56%) had stable disease.
The 2-year PFS is 78±8.
The 2-year PFS is 78±8.
In summary, smetinib is well tolerated in children with relapsed/progressive OPHGs.
Sumetinib is well tolerated in children with relapsed/progressive OPHGs, and it can also improve imaging remission, PFS and visual prognosis, and prolong the stable period of disease.
Original source:
Fangusaro Jason, Onar-Thomas Arzu, Poussaint Tina Young et al.
oup.
com/neuro-oncology/advance-article-abstract/doi/10.
1093/neuonc/noab047/6149924?redirectedFrom=fulltext">A Phase 2 Trial of Selumetinib in Children with Recurrent Optic Pathway and Hypothalamic Low-Grade Glioma without NF1: A Pediatric Brain Tumor Consortium Study in this message